Alto Neuroscience (ANRO) EBITDA (2023 - 2026)

Alto Neuroscience has disclosed EBITDA across 4 years of filings, most recently posting -$27.1 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$27.1 million, down 73.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.8 million (down 11.34% YoY), and the FY2025 annual result was -$66.4 million, up 3.27% from the prior year.
• EBITDA came in at -$27.1 million for Q1 2026 at Alto Neuroscience, down from -$17.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$7.2 million in Q1 2023 to a low of -$27.1 million in Q1 2026.
• The 4-year median for EBITDA is -$15.7 million (2025), against an average of -$15.4 million.
• Across the five-year window, EBITDA sank 101.0% in 2024 and gained 20.84% in 2025, its largest moves.
• Alto Neuroscience's EBITDA stood at -$11.8 million in 2023, then slumped by 44.47% to -$17.0 million in 2024, then dropped by 0.34% to -$17.1 million in 2025, then slumped by 59.12% to -$27.1 million in 2026.
• The last three EBITDA figures came in at -$27.1 million (Q1 2026), -$17.1 million (Q4 2025), and -$15.0 million (Q3 2025), per Business Quant data.